Non-Alcoholic Steatohepatitis Biomarkers Market Size, Trends, Analysis, and Outlook By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, Others), By End-user (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes), by Region, Country, Segment, and Companies, 2024-2030
The global Non-Alcoholic Steatohepatitis Biomarkers market size is poised to register 23.3% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Non-Alcoholic Steatohepatitis Biomarkers market across By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, Others), By End-user (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes).
The Non-Alcoholic Steatohepatitis (NASH) Biomarkers market is experiencing significant growth attributed to the rising prevalence of non-alcoholic fatty liver disease (NAFLD), advancements in biomarker discovery, and the growing demand for non-invasive diagnostic tools for liver fibrosis assessment. NASH biomarkers refer to biological indicators used to detect and monitor the progression of non-alcoholic steatohepatitis, a severe form of NAFLD characterized by liver inflammation and fibrosis. Key drivers of market growth include the increasing burden of metabolic disorders such as obesity and diabetes, the rising awareness about NASH-related complications including liver cirrhosis and hepatocellular carcinoma, and the limitations of liver biopsy as the gold standard for NASH diagnosis and staging. Additionally, the development of novel blood-based, imaging-based, and genetic biomarkers for NASH detection, the implementation of precision medicine approaches for patient stratification, and the emergence of multi-biomarker panels for comprehensive liver fibrosis assessment are driving innovation in the market. Moreover, the growing investment in NASH biomarker research, the expansion of clinical trial pipelines for NASH diagnostics and therapeutics, and the regulatory approvals for new diagnostic tests are fueling market expansion. Furthermore, strategic collaborations between biotechnology companies, academic research institutions, and pharmaceutical companies are driving biomarker validation efforts and ensuring the commercialization of reliable and accurate NASH biomarker assays for clinical use.
Non-Alcoholic Steatohepatitis Biomarkers Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Non-Alcoholic Steatohepatitis Biomarkers market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Non-Alcoholic Steatohepatitis Biomarkers survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Non-Alcoholic Steatohepatitis Biomarkers industry.
Key market trends defining the global Non-Alcoholic Steatohepatitis Biomarkers demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Non-Alcoholic Steatohepatitis Biomarkers industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Non-Alcoholic Steatohepatitis Biomarkers companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Non-Alcoholic Steatohepatitis Biomarkers industry
Leading Non-Alcoholic Steatohepatitis Biomarkers companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Non-Alcoholic Steatohepatitis Biomarkers companies.
Non-Alcoholic Steatohepatitis Biomarkers Market Study- Strategic Analysis Review
The Non-Alcoholic Steatohepatitis Biomarkers market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
The Non-Alcoholic Steatohepatitis Biomarkers industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Non-Alcoholic Steatohepatitis Biomarkers Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Non-Alcoholic Steatohepatitis Biomarkers market segments. Similarly, Strong end-user demand is encouraging Canadian Non-Alcoholic Steatohepatitis Biomarkers companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Non-Alcoholic Steatohepatitis Biomarkers market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Non-Alcoholic Steatohepatitis Biomarkers industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Non-Alcoholic Steatohepatitis Biomarkers market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Non-Alcoholic Steatohepatitis Biomarkers in Asia Pacific. In particular, China, India, and South East Asian Non-Alcoholic Steatohepatitis Biomarkers markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Non-Alcoholic Steatohepatitis Biomarkers market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Non-Alcoholic Steatohepatitis Biomarkers.
Non-Alcoholic Steatohepatitis Biomarkers Market Company Profiles
The global Non-Alcoholic Steatohepatitis Biomarkers market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AstraZeneca, BioPredictive, Bristol-Myers Squibb Company, Exalenz Bioscience Ltd, GENFIT, Laboratory Corp of America Holdings., Pfizer Inc, Prometheus Laboratories., Quest Diagnostics, Siemens Medical Solutions USA Inc
Recent Non-Alcoholic Steatohepatitis Biomarkers Market Developments
The global Non-Alcoholic Steatohepatitis Biomarkers market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Non-Alcoholic Steatohepatitis Biomarkers Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
By Type
Serum Biomarkers
Hepatic Fibrosis Biomarkers
Apoptosis Biomarkers
Oxidative Stress Biomarkers
Others
By End-user
Pharma & CRO Industry
Hospitals
Diagnostic Labs
Academic Research Institutes
Geographical Segmentation:
AstraZeneca
BioPredictive
Bristol-Myers Squibb Company
Exalenz Bioscience Ltd
GENFIT
Laboratory Corp of America Holdings.
Pfizer Inc
Prometheus Laboratories.
Quest Diagnostics
Siemens Medical Solutions USA Inc
Formats Available: Excel, PDF, and PPT
The Non-Alcoholic Steatohepatitis (NASH) Biomarkers market is experiencing significant growth attributed to the rising prevalence of non-alcoholic fatty liver disease (NAFLD), advancements in biomarker discovery, and the growing demand for non-invasive diagnostic tools for liver fibrosis assessment. NASH biomarkers refer to biological indicators used to detect and monitor the progression of non-alcoholic steatohepatitis, a severe form of NAFLD characterized by liver inflammation and fibrosis. Key drivers of market growth include the increasing burden of metabolic disorders such as obesity and diabetes, the rising awareness about NASH-related complications including liver cirrhosis and hepatocellular carcinoma, and the limitations of liver biopsy as the gold standard for NASH diagnosis and staging. Additionally, the development of novel blood-based, imaging-based, and genetic biomarkers for NASH detection, the implementation of precision medicine approaches for patient stratification, and the emergence of multi-biomarker panels for comprehensive liver fibrosis assessment are driving innovation in the market. Moreover, the growing investment in NASH biomarker research, the expansion of clinical trial pipelines for NASH diagnostics and therapeutics, and the regulatory approvals for new diagnostic tests are fueling market expansion. Furthermore, strategic collaborations between biotechnology companies, academic research institutions, and pharmaceutical companies are driving biomarker validation efforts and ensuring the commercialization of reliable and accurate NASH biomarker assays for clinical use.
Non-Alcoholic Steatohepatitis Biomarkers Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Non-Alcoholic Steatohepatitis Biomarkers market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Non-Alcoholic Steatohepatitis Biomarkers survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Non-Alcoholic Steatohepatitis Biomarkers industry.
Key market trends defining the global Non-Alcoholic Steatohepatitis Biomarkers demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Non-Alcoholic Steatohepatitis Biomarkers industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Non-Alcoholic Steatohepatitis Biomarkers companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Non-Alcoholic Steatohepatitis Biomarkers industry
Leading Non-Alcoholic Steatohepatitis Biomarkers companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Non-Alcoholic Steatohepatitis Biomarkers companies.
Non-Alcoholic Steatohepatitis Biomarkers Market Study- Strategic Analysis Review
The Non-Alcoholic Steatohepatitis Biomarkers market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
- Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
- Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
- Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
- Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
The Non-Alcoholic Steatohepatitis Biomarkers industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Non-Alcoholic Steatohepatitis Biomarkers Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Non-Alcoholic Steatohepatitis Biomarkers market segments. Similarly, Strong end-user demand is encouraging Canadian Non-Alcoholic Steatohepatitis Biomarkers companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Non-Alcoholic Steatohepatitis Biomarkers market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Non-Alcoholic Steatohepatitis Biomarkers industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Non-Alcoholic Steatohepatitis Biomarkers market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Non-Alcoholic Steatohepatitis Biomarkers in Asia Pacific. In particular, China, India, and South East Asian Non-Alcoholic Steatohepatitis Biomarkers markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Non-Alcoholic Steatohepatitis Biomarkers market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Non-Alcoholic Steatohepatitis Biomarkers.
Non-Alcoholic Steatohepatitis Biomarkers Market Company Profiles
The global Non-Alcoholic Steatohepatitis Biomarkers market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AstraZeneca, BioPredictive, Bristol-Myers Squibb Company, Exalenz Bioscience Ltd, GENFIT, Laboratory Corp of America Holdings., Pfizer Inc, Prometheus Laboratories., Quest Diagnostics, Siemens Medical Solutions USA Inc
Recent Non-Alcoholic Steatohepatitis Biomarkers Market Developments
The global Non-Alcoholic Steatohepatitis Biomarkers market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Non-Alcoholic Steatohepatitis Biomarkers Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
- Pricing Analysis
- Value Chain Analysis
- SWOT Profile
- Market Dynamics- Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- Macroeconomic Impact Analysis
- Case Scenarios- Low, Base, High
By Type
Serum Biomarkers
Hepatic Fibrosis Biomarkers
Apoptosis Biomarkers
Oxidative Stress Biomarkers
Others
By End-user
Pharma & CRO Industry
Hospitals
Diagnostic Labs
Academic Research Institutes
Geographical Segmentation:
- North America (3 markets)
- Europe (6 markets)
- Asia Pacific (6 markets)
- Latin America (3 markets)
- Middle East Africa (5 markets)
AstraZeneca
BioPredictive
Bristol-Myers Squibb Company
Exalenz Bioscience Ltd
GENFIT
Laboratory Corp of America Holdings.
Pfizer Inc
Prometheus Laboratories.
Quest Diagnostics
Siemens Medical Solutions USA Inc
Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY
1.1 Non-Alcoholic Steatohepatitis Biomarkers Market Overview and Key Findings, 2024
1.2 Non-Alcoholic Steatohepatitis Biomarkers Market Size and Growth Outlook, 2021- 2030
1.3 Non-Alcoholic Steatohepatitis Biomarkers Market Growth Opportunities to 2030
1.4 Key Non-Alcoholic Steatohepatitis Biomarkers Market Trends and Challenges
1.4.1 Non-Alcoholic Steatohepatitis Biomarkers Market Drivers and Trends
1.4.2 Non-Alcoholic Steatohepatitis Biomarkers Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Non-Alcoholic Steatohepatitis Biomarkers Companies
2. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET SIZE OUTLOOK TO 2030
2.1 Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook, USD Million, 2021- 2030
2.2 Non-Alcoholic Steatohepatitis Biomarkers Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Type
Serum Biomarkers
Hepatic Fibrosis Biomarkers
Apoptosis Biomarkers
Oxidative Stress Biomarkers
Others
By End-user
Pharma & CRO Industry
Hospitals
Diagnostic Labs
Academic Research Institutes
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, 2025
5.2 Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Non-Alcoholic Steatohepatitis Biomarkers Market, 2025
5.5 Europe Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Type, 2021- 2030
5.6 Europe Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Non-Alcoholic Steatohepatitis Biomarkers Market, 2025
5.8 North America Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Type, 2021- 2030
5.9 North America Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Non-Alcoholic Steatohepatitis Biomarkers Market, 2025
5.11 South America Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Type, 2021- 2030
5.12 South America Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market, 2025
5.14 Middle East Africa Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook and Revenue Growth Forecasts
6.2 US Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
7. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS COMPANY PROFILES
8.1 Profiles of Leading Non-Alcoholic Steatohepatitis Biomarkers Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
AstraZeneca
BioPredictive
Bristol-Myers Squibb Company
Exalenz Bioscience Ltd
GENFIT
Laboratory Corp of America Holdings.
Pfizer Inc
Prometheus Laboratories.
Quest Diagnostics
Siemens Medical Solutions USA Inc
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
1.1 Non-Alcoholic Steatohepatitis Biomarkers Market Overview and Key Findings, 2024
1.2 Non-Alcoholic Steatohepatitis Biomarkers Market Size and Growth Outlook, 2021- 2030
1.3 Non-Alcoholic Steatohepatitis Biomarkers Market Growth Opportunities to 2030
1.4 Key Non-Alcoholic Steatohepatitis Biomarkers Market Trends and Challenges
1.4.1 Non-Alcoholic Steatohepatitis Biomarkers Market Drivers and Trends
1.4.2 Non-Alcoholic Steatohepatitis Biomarkers Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Non-Alcoholic Steatohepatitis Biomarkers Companies
2. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET SIZE OUTLOOK TO 2030
2.1 Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook, USD Million, 2021- 2030
2.2 Non-Alcoholic Steatohepatitis Biomarkers Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Type
Serum Biomarkers
Hepatic Fibrosis Biomarkers
Apoptosis Biomarkers
Oxidative Stress Biomarkers
Others
By End-user
Pharma & CRO Industry
Hospitals
Diagnostic Labs
Academic Research Institutes
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, 2025
5.2 Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Non-Alcoholic Steatohepatitis Biomarkers Market, 2025
5.5 Europe Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Type, 2021- 2030
5.6 Europe Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Non-Alcoholic Steatohepatitis Biomarkers Market, 2025
5.8 North America Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Type, 2021- 2030
5.9 North America Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Non-Alcoholic Steatohepatitis Biomarkers Market, 2025
5.11 South America Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Type, 2021- 2030
5.12 South America Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market, 2025
5.14 Middle East Africa Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Non-Alcoholic Steatohepatitis Biomarkers Market Size Outlook and Revenue Growth Forecasts
6.2 US Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Non-Alcoholic Steatohepatitis Biomarkers Industry Drivers and Opportunities
7. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS COMPANY PROFILES
8.1 Profiles of Leading Non-Alcoholic Steatohepatitis Biomarkers Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
AstraZeneca
BioPredictive
Bristol-Myers Squibb Company
Exalenz Bioscience Ltd
GENFIT
Laboratory Corp of America Holdings.
Pfizer Inc
Prometheus Laboratories.
Quest Diagnostics
Siemens Medical Solutions USA Inc
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
